文献速递胸部肿瘤放疗姑息放疗与转移瘤

肺癌立体定向体部放疗后区域淋巴结复发:复发模式、治疗方式与临床结局(KROG 21-09)

Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09).
PubMed 文献 · Radiother Oncol · 2023-02-21

该多中心回顾性研究分析了114例肺癌SBRT后以区域淋巴结为首发复发患者的复发模式与治疗结局。约半数患者仅有区域淋巴结复发,常见复发部位为同侧肺门、同侧上纵隔和隆突下淋巴结站。挽救性放疗组总生存优于姑息治疗组,挽救性放疗、姑息治疗及同时远处转移与临床结局相关。

要点

  • 约半数患者区域淋巴结复发局限于局部区域,最常见同时复发为远处转移(38.6%)。
  • 挽救性放疗组总生存优于姑息治疗组(p=0.025)。
  • 多因素分析显示挽救性放疗与改善无进展生存和总生存相关。

核心结论

  • 许多区域淋巴结复发病例局限于患者的局部区域,适当的治疗可改善这些患者的预后。

研究设计与样本

  • 多中心回顾性研究,回顾性分析了114例肺癌SBRT后以区域淋巴结复发为首发复发的患者病历资料。
  • 复发模式分为局部复发、区域复发和远处转移,分析包括无进展生存和总生存在内的临床结局。

主要发现

  • 半数患者仅有区域淋巴结复发,最常见的同时复发为远处转移(38.6%)。
  • 区域复发常见部位为同侧肺门(47.2%)、同侧上纵隔(40.6%)和隆突下(42.5%)淋巴结站。
  • 24例(21.1%)患者接受挽救性放疗,44例(38.6%)患者接受姑息治疗,挽救性放疗组观察到更好的总生存(p=0.025)。
  • 挽救性放疗组1年无进展生存率和总生存率分别为27.7%和55.2%,姑息治疗组分别为14.0%和39.9%,无额外治疗组分别为22.8%和26.8%。
  • 多因素分析显示挽救性放疗(无进展生存,HR 0.463,p=0.050;总生存,HR 0.312,p=0.002)、姑息治疗(无进展生存,HR 0.436,p=0.013;总生存,HR 0.553,p=0.050)和同时远处转移(无进展生存,HR 2.335,p=0.005;总生存,HR 1.726,p=0.054)影响临床结局。

临床怎么用

  • 原文结论指出许多区域淋巴结复发病例局限于局部区域,适当的治疗可改善这些患者的预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present the multi-institutional data on patterns of recurrence, treatment approaches, and clinical outcomes for regional lymph node (LN) recurrence after stereotactic body radiation therapy (SBRT) for primary lung cancer. MATERIALS AND METHODS: The medical records of 114 patients who experienced regional LN recurrence as the first recurrence after lung SBRT were retrospectively reviewed. Patterns of recurrence were classified as local recurrence, regional recurrence, and distant metastasis. Clinical outcomes including progression-free survival (PFS) and overall survival (OS) were analyzed. RESULTS: Half of the patients had regional LN recurrence only. The most common simultaneous recurrence was distant metastasis (38.6 %). Common sites of regional recurrence were ipsilateral hilar (47.2 %), ipsilateral upper mediastinal (40.6 %), and subcarinal (42.5 %) LN stations. 24 (21.1 %) patients underwent salvage radiation therapy (RT), and 44 (38.6 %) patients underwent palliative treatment. Better OS was observed in the salvage RT group (p = 0.025). The 1-year PFS and OS rates were 27.7 % and 55.2 %, respectively, with salvage RT, 14.0 % and 39.9 %, respectively, with palliative treatment, and 22.8 % and 26.8 %, respectively, with no additional treatment. Multivariate analysis showed that salvage RT (PFS, HR 0.463, p = 0.050; OS, HR 0.312, p = 0.002), palliative treatment (PFS, HR 0.436, p = 0.013; OS, HR 0.553, p = 0.050), and simultaneous distant metastasis (PFS, HR 2.335, p = 0.005; OS, HR 1.726, p = 0.054) affected clinical outcomes. CONCLUSION: Many cases of regional LN recurrence are confined to the locoregional area of patients, and appropriate treatment can improve the prognosis of these patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lee TH, Shin H, Ahn YC, et al. Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09). Radiother Oncol. 2023. PMID: 36822359. doi:10.1016/j.radonc.2023.109572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。